'Atherothrombosis-Associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Perez Sanchez C ^a   Aguirre, M A ^a   Ruiz Limon P ^a   Barbarroja, N ^a   Jimenez Gomez Y ^a   De La Rosa, I Arias ^a   Rodriguez Ariza, A ^a   Collantes Estevez E ^a   Segui, P ^a   Velasco, F ^a   Cuadrado, M J ^b   Teruel, R ^c   Gonzalez Conejero R ^c   Martinez C ^a   López Pedrera, Ch ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; MICRORNA; MIRN124 MICRORNA, HUMAN; MIRN125 MICRORNA, HUMAN; MIRN146 MICRORNA, HUMAN; MIRN155 MICRORNA, HUMAN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL WALL THICKNESS; BIOLOGY; BLOOD; CASE CONTROL STUDY; CYTOLOGY; FEMALE; GENETIC EPIGENESIS; GENETIC TRANSFECTION; HUMAN; INFLAMMATION; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; NEUTROPHIL; OXIDATIVE STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BIOMARKERS; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICRORNAS; MIDDLE AGED; MONOCYTES; NEUTROPHILS; OXIDATIVE STRESS; THROMBOSIS; TRANSFECTION;

EID: 84981276903     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31375     Document Type: Article

References (60)

1. Ames, P. R. et al. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J. Thromb Haemost. 7, 537-542 (2009).
2. Alves, J. D. & Grima, B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: A gateway to atherosclerosis. Curr. Rheumatol Rep. 5, 383-390 (2003).
3. Perez-Sanchez, C. et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 119, 5859-5870 (2012).
4. Pierangeli, S. S. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99, 1997-2002 (1999).
5. Meroni, P. L. et al. Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J. Autoimmun. 15, 237-240 (2000).
6. Dobado-Berrios, P. M., López-Pedrera, C., Velasco, F. & Cuadrado, M. J. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum. 44, 2467-2476 (2001).
7. Means, T. K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin Invest. 115, 407-417 (2005).
8. Munoz, L. E., Gaipl, U. S. & Herrmann, M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev. 7, 594-597 (2008).
9. Ruiz-Limon, P. et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 74, 1450-1458 (2015).
10. Lai, K. N., Leung, J. C., Lai, K. B. & Lai, C. K. Effect of anti-DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor-beta, and nitric oxide synthase in cultured endothelial cells. Scand J. Rheumatol. 26, 461-467 (1997).
11. Lai, K. N., Leung, J. C., Lai, K. B., Wong, K. C. & Lai, C. K. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clin Immunol Immunopathol. 81, 229-238 (1996).
12. Neng Lai, K., Leung, J. C., Bik Lai, K., Li, P. K. & Lai, C. K. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J. Pathol. 178, 451-457 (1996).
13. Shin, M. S. et al. Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J. Immunol. 190, 1407-1415 (2013).
14. Kirou, K. A. et al. Coordinate overexpression of interferon-Alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004).
15. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100, 2610-2615 (2003).
16. Perez-Sanchez, C. et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. 74, 1441-1449 (2015).
17. López-Pedrera, C. et al. Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. Clin Dev Immunol. 2012, 9746-9748 (2012).
18. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
19. Bartel, D. P. MicroRNAs: Target recognition and regulatory functions. Cell 136, 215-233 (2009).
20. Shen, N., Liang, D., Tang, Y., de Vries, N. & Tak, P. P. MicroRNAs-novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol. 8, 701-709 (2012).
21. Miao, C. G. et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal 25, 1828-1836 (2013).
22. Amarilyo, G. & La Cava, A. miRNA in systemic lupus erythematosus. Clin Immunol. 144, 26-31 (2012).
23. Teruel, R. et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J. Thromb Haemost. 9, 1985-1992 (2011).
24. Aranda, J. F., Madrigal-Matute, J., Rotllan, N. & Fernández-Hernando, C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med. 64, 31-39 (2013).
25. Laganà, A. et al. miRo: A miRNA knowledge base. Database. (Oxford) 2009, bap008 (2009).
26. Madrigal-Matute, J., Rotllan, N., Aranda, J. F. & Fernández-Hernando, C. MicroRNAs and atherosclerosis. Curr Atheroscler Rep. 15, 322 (2013).
27. Alexander, C. & Rietschel, E. T. Bacterial lipopolysaccharides and innate immunity. Endotoxin Res. 7, 167-202 (2001).
28. López-Pedrera, C., Aguirre, M. Á., Barbarroja, N. & Cuadrado, M. J. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J. Biomed Biotechnol. 2010, 607084 (2010).
29. Legein, B., Temmerman, L., Biessen, E. A. & Lutgens, E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 70, 3847-3869 (2013).
30. Nishiguchi, T., Imanishi, T. & Akasaka, T. MicroRNAs and Cardiovascular Diseases. BioMed Research International. 2015, 682857, doi: 10.1155/2015/682857 (2015).
31. Donners, M. M. et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 7, e35877 (2012).
32. Wang, H. J. et al. MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. Mediators Inflamm. 2014, 379537 (2014).
33. Chistiakov, D. A., Sobenin, I. A., Orekhov, A. N. & Bobryshev, Y. V. Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. Biomed Res Int. 2015, 354517 (2015).
34. Chen, T. et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDLstimulated monocyte/macrophages. Cardiovasc Res. 83, 131-139 (2009).
35. Dai, R. & Ahmed, S. A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 157, 163-179 (2011).
36. Tang, Y. et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065-1075 (2009).
37. Boldin, M. P. et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp Med. 208, 1189-1201 (2011).
38. Stagakis, E. et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 70, 1496-1506 (2011).
39. Thai, T. H. et al. Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proc Natl Acad Sci USA 110, 20194-20199 (2013).
40. Stanczyk, J. et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 1001-1009 (2008).
41. Long, L. et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol. 2013, 296139 (2013).
42. Zhao, X. et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 62, 3425-3435 (2010).
43. Nakamachi, Y., Kawano, S. & Takenokuchi, M. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294-1304 (2009).
44. Barbarroja, N. et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 34, 2706-2716 (2014).
45. Rippo, M. R. et al. MitomiRs in human inflamm-Aging: A hypothesis involving miR-181a, miR-34a and miR-146a. Exp Gerontol. 56, 154-163 (2014).
46. Olivieri, F. et al. MiR-146a as marker of senescence-Associated pro-inflammatory status in cells involved in vascular remodelling. Age (Dordr) 35, 1157-1172 (2013).
47. Barrey, E. et al. Pre-microRNA and mature microRNA in human mitochondria. PLoS One 6, e20220 (2011).
48. Chafin, C. B., Regna, N. L., Hammond, S. E. & Reilly, C. M. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharmacol. 17, 894-906 (2013).
49. Chan, E. S. & Cronstein, B. N. Methotrexate-how does it really work? Nat Rev Rheumatol. 6, 175-178 (2010).
50. Chauhan, S. K., Singh, V. V., Rai, R., Rai, M. & Rai, G. Differential microRNA profile and post-Transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities. J. Clin Immunol. 34, 491-503 (2014).
51. Yamakuchi, M. MicroRNAs in Vascular Biology. Int J Vasc Med. 2012, 794898, doi: 10.1155/2012/794898 (2012).
52. Sun, X. et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. Clin Invest. 122, 1973-1990 (2012).
53. Suárez, Y., Wang, C., Manes, T. D. & Pober, J. S. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J. Immunol. 184, 21-25 (2010).
54. Zhu, N. et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 215, 286-293 (2011).
55. Wiesen, J. L. & Tomasi, T. B. Dicer is regulated by cellular stresses and interferons. Mol Immunol. 46, 1222-1228 (2009).
56. Suárez, Y., Fernández-Hernando, C., Pober, J. S. & Sessa, W. C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res. 100, 1164-1173 (2007).
57. Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64-71 (2008).
58. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
59. Krek, A. et al. Combinatorial microRNA target predictions. Nat.Genet. 37, 495-500 (2005).
60. John, B. et al. Human MicroRNA targets. PLoS. Biol 2, e363 (2004).